MEDICONSEIL : revenue, balance sheet and financial ratios

MEDICONSEIL is a French company founded 19 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in VALENCE (26000), this company of category PME shows in 2022 a revenue of 1.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - MEDICONSEIL (SIREN 493250807)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue N/C N/C N/C 1 179 792 € N/C N/C N/C 1 156 999 € N/C N/C 1 075 412 € 1 163 950 €
Net income 397 256 € 454 680 € 363 878 € 160 587 € 171 556 € 59 659 € 89 425 € 198 954 € 134 222 € 236 190 € 226 198 € 299 961 €
EBITDA N/C N/C N/C 352 403 € N/C N/C N/C 276 779 € N/C N/C 354 671 € 451 417 €
Net margin N/C N/C N/C 13.6% N/C N/C N/C 17.2% N/C N/C 21.0% 25.8%

Revenue and income statement

In 2025, MEDICONSEIL generates positive net income of 397 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2014-2025: 300 k€ -> 397 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

397 256 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 62%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

62.103%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

56.1%

Solvency indicators evolution
MEDICONSEIL

Sector positioning

Debt ratio
0.0 2025
2023
2024
2025
Q1: 0.0
Med: 3.67
Q3: 28.55
Excellent

In 2025, the debt ratio of MEDICONSEIL (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
62.1% 2025
2023
2024
2025
Q1: 26.28%
Med: 43.48%
Q3: 62.04%
Excellent +9 pts over 3 years

In 2025, the financial autonomy of MEDICONSEIL (62.1%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 250.38. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

250.383

Liquidity indicators evolution
MEDICONSEIL

Sector positioning

Liquidity ratio
250.38 2025
2023
2024
2025
Q1: 147.44
Med: 215.05
Q3: 310.05
Good

In 2025, the liquidity ratio of MEDICONSEIL (250.38) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
MEDICONSEIL

Positioning of MEDICONSEIL in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of MEDICONSEIL is estimated at 326 352 € (range 124 211€ - 1 191 796€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
124 transactions
124k€ 326k€ 1191k€
326 352 € Range: 124 211€ - 1 191 796€
NAF 5 all-time

Valuation method used

Net Income Multiple
397 256 € × 0.8x = 326 352 €
Range: 124 212€ - 1 191 796€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare MEDICONSEIL with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about MEDICONSEIL

What is the revenue of MEDICONSEIL ?

The revenue of MEDICONSEIL in 2022 is 1.2 M€.

Is MEDICONSEIL profitable?

Yes, MEDICONSEIL generated a net profit of 397 k€ in 2025.

Where is the headquarters of MEDICONSEIL ?

The headquarters of MEDICONSEIL is located in VALENCE (26000), in the department Drome.

Where to find the tax return of MEDICONSEIL ?

The tax return of MEDICONSEIL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does MEDICONSEIL operate?

MEDICONSEIL operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.